AAOS approves diagnostic and treatment criteria for osteoarthritis of the hip

Posted On December 13, 2017 By OrthoSpineNews In Recon, Top Stories /

ROSEMONT, Ill., Dec. 12, 2017 /PRNewswire-USNewswire/ — The American Academy of Orthopaedic Surgeons (AAOS) Board of Directors approved new Appropriate Use Criteria (AUC) for Management of Osteoarthritis of the Hip.

The AAOS AUCs provide clinicians with algorithms on how to optimally treat an orthopaedic injury or condition, including hypothetical scenarios and possible treatments, ranked for appropriateness based on the latest research and clinical expertise and experience.

The new AUC supports the Clinical Practice Guideline, “Management of Osteoarthritis of the Hip” that strongly recommends:

The use of pre-surgical treatments to ease pain and improve mobility, including corticosteroid injections, physical therapy and non-narcotic medication (specifically acetaminophen, non-steroidal anti-inflammatory drugs or tramadol) for pain.
Both anterior and posterior approaches for total hip replacement (THR) surgery.

In addition, the new criteria highlight when “hip replacement may be appropriate even when patients have modifiable risk factors, such as obesity, mental health disorders, smoking and diabetes,” said Robert H. Quinn, MD, AAOS AUC section leader on the Committee on Evidence-Based Quality and Value.

For example, “some patients, who have worked closely with their medical team to best mitigate these risk factors, might be considered on an individual basis” for surgery, said Dr. Quinn. “In these instances, the doctor and patient must weigh the benefits and risks of surgery. At the end of the day it’s one surgeon and one patient, and hopefully both are considering the optimal treatment, based on the patient’s particular condition and diagnosis.”

The AUC and CPG, “Management of Osteoarthritis of the Hip,” are available through the AAOS OrthoGuidelines website and mobile app.

More Information about the AAOS
With more than 38,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS, at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions. ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Facebook.org/AAOS1
Twitter.com/AAOS1
Instagram.com/AAOS_1

SOURCE American Academy of Orthopaedic Surgeons

VEXIM Announces the Results of the Simplified Tender Offer Initiated by Stryker

Posted On December 13, 2017 By OrthoSpineNews In Financial /

December 12, 2017

BALMA, France–(BUSINESS WIRE)–Regulatory News:

VEXIM (Paris:ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures listed on Euronext Growth (FR0011072602 – ALVXM), announces that the simplified public tender offer for the shares and BSAAR warrants of VEXIM (the “offer”), initiated by Stryker France MM Holding SAS (“Stryker”), has closed. The public tender offer was opened from November 16, 2017, to December 6, 2017.

The results were published yesterday by the French financial market authority (Autorité des marchés financiers, the “AMF”). Stryker, which already owned over 50% of the share capital and voting rights of VEXIM at the date of the filing of the public tender offer with the AMF, acquired an additional 4,036,406 shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM. Stryker now holds 8,416,399 shares of VEXIM representing 92.19 % of its share capital and at least 91.56% of its voting rights.

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the Masterflow^TM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. VEXIM has been listed on Euronext Growth Paris since May 3^rd 2012. For further information, please visit www.vexim.com

SpineJack®, an innovative implant for treating Vertebral Compression Fractures
The SpineJack® is designed to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

Nom : VEXIM
Code ISIN : FR0011072602
Code mnémonique : ALVXM

Contacts

VEXIM
Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
Tél. : +33 5 61 48 48 38
investisseur@vexim.com
or
PRESS RELATIONS
ALIZE RP
Caroline Carmagnol / Wendy Rigal
Tél. : +33 1 44 54 36 66 / Tél. : +33 6 48 82 18 94
vexim@alizerp.com

THINK Surgical, Inc. Receives CE Mark Approval for the TSolution One® Surgical System for Total Knee Arthroplasty

Posted On December 13, 2017 By OrthoSpineNews In Recon, Regulatory, Robotics /

FREMONT, Calif., Dec. 11, 2017 /PRNewswire/ — THINK Surgical Inc., a global medical device manufacturer of the only active robotic surgical system for orthopaedic surgery, announces that it has received CE Mark approval for the TSolution One® Surgical System, bringing active robotic precision to Total Knee Arthroplasty (TKA).

The TSolution One Surgical System first entered the European market in 2015 when it received CE Mark approval for Total Hip Arthroplasty (THA). Currently, the system has 510(k) clearance for THA in the United States and four centers are enrolling patients for an IDE clinical study for TKA. Earlier in the year, the TSolution One Surgical System received Korean-FDA clearance for both THA and TKA. It also received approval for sale in Israel by the Ministry of Health for THA.

“We are pleased to offer one of the most advanced technologies in Total Knee Replacement through the TSolution One Surgical System to the European market and other countries that rely on the CE Mark,” said John Hahn, CEO of THINK Surgical, Inc. “Obtaining the CE Mark represents a key milestone towards continuing the global commercialization of our differentiated robotic technology and our commitment to improving patients’ lives and partnering with surgeons to transform orthopedic surgery.”

TSolution One is a robotic system that enables surgeons to create the patient’s personalized pre-surgical joint replacement plan, using CT-based 3D planning and the system’s open implant library to achieve an optimized surgical plan. During surgery, the robot precisely executes the patient’s individual surgical plan by removing diseased bone and preparing the bone cavity and joint surface with sub-millimeter dimensional accuracy.¹THINK’s active robotic technology has been shown to improve joint replacement implant fit and alignment as compared to conventional joint replacement surgery.² Accurate implant fit and alignment may be responsible for reduced postoperative pain, complications, and improved patient function.^3,4

¹Paul HA, Bargar WL, Mittlestadt B, Musits B, Taylor RH, Kazanzides P, et al. Development of a Surgical Robot for Cementless Total Hip Arthroplasty. Clin Orthop Relat Res 1992;285:57–66

²Netravali, Nathan et al., “A Perspective on Robotic Assistance for Knee Arthroplasty” Advances in Orthopedics (2013): DOI http://dx.doi.org/10.1155/2013/970703

³P. F. Choong, M. M. Dowsey, and J. D. Stoney, “Does accurate anatomical alignment result in better function and quality of life? Comparing conventional and computer-assisted total knee arthroplasty,” Journal of Arthroplasty, vol. 24, no. 4, pp. 560–569, 2009.

⁴Barrack RL. Dislocation after total hip arthroplasty: Implant design and orientation. J Am Acad Orthop Surg. 2003;11(2):89-99.

About THINK Surgical, Inc.
THINK Surgical, Inc. is committed to the future of orthopaedic surgery and to improving patient care through the development of leading-edge precision technology. THINK Surgical develops, manufactures, and markets the only active robotic surgical system for orthopaedic surgery.

For more information, visit www.THINKSurgical.com.
TSolution One® is a registered trademark of THINK Surgical, Inc.

Contact: Nancy Heinzer
510-249-2318
info@thinksurgical.com

Related Links
THINK Surgical website

SOURCE THINK Surgical, Inc.

DePuy Synthes launches CONCORDE Clear MIS Discectomy Device to simplify spinal fusion surgery

Posted On December 13, 2017 By OrthoSpineNews In Spine /

December 12, 2017

DePuy Synthes today announced the launch of CONCORDE™ Clear MIS Discectomy Device, a surgical solution designed to simplify discectomy in minimally invasive spinal fusion surgery. Now available in Europe, the Middle East and Africa (EMEA), the single-use tool allows surgeons to complete the degenerated disc-removing process (discectomy) more efficiently than using traditional tools, while increasing the amount of disc material removed.

Lumbar disc herniation or prolapse accounts for 5% of all low back pain problems; it is the leading cause of radiating nerve root pain (sciatica) and one of the most common reasons for spinal fusion surgery. It is estimated that 140,000 discectomies for interbody fusion procedures will be performed across EMEA in 2018, of which a growing number will be minimally invasive. According to internal data from DePuy Synthes, minimally invasive surgery (MIS) is the fastest growing category in spinal fusion surgery as it is shown to result in fewer complications compared to open surgery in treating degenerative disc disease. As this procedure becomes more popular, there is a significant need to simplify MIS techniques and develop new instruments that can improve the efficiency of the procedure, while maximizing disc removal.

Discectomy in spinal fusion surgery typically requires the surgeon to work through a small surgical field with limited visibility. Traditionally, it requires several instruments and multiple instrument passes to make sure the disc is cleared and the endplates of the vertebrae are prepped for implants, which increases the risk of injury to the nerve root. The CONCORDE Clear Device is a single-use instrument that removes the degenerated disc and prepares the endplates using readily-available, standard hospital suction. The clear handle also allows surgeons to immediately see the collection of disc material. This simplified approach requires fewer tool passes and instrument exchanges when compared to traditional techniques, and removes a larger disc volume. This allows surgeons to complete the surgery more efficiently, which could lead to improved patient outcomes.

Dr. Gerd Bordon of Hospital de Manises, Valencia, Spain, commented:

CONCORDE Clear is an ideal tool to enhance discectomy procedures. I find it simple to use, it increases the efficiency of my procedures and improves the cleaning of the disc space. I believe it will lead to better patient outcomes in spinal fusion surgery.

The launch of the CONCORDE Clear Device follows DePuy Synthes’ October release of the VIPER PRIME™ System. The VIPER PRIME System is also designed to improve efficiency in spinal surgery. The inserter reduces the number of instruments and the number of instrument passes to place a pedicle screw using a minimally invasive technique.

“The CONCORDE Clear MIS Discectomy Device is a true innovation that embodies our mission to make spinal fusion surgery less invasive for patients and less complicated for surgeons,” said Jordy Winters, Lead, DePuy Synthes Spine EMEA. “Both the CONCORDE Clear Device and the VIPER PRIME System are clear examples of how we continue to innovate in order to meet the increasing demand for MIS in Spine. In swift succession, we have provided two procedural solutions that are intended to make spinal fusion procedures more reproducible for surgeons, and result in better outcomes for patients.”

Source:

http://www.depuysynthes.com/

Camber Spine Announces FDA Clearance Of Spira™-C Open Matrix Cervical Interbody

Posted On December 11, 2017 By OrthoSpineNews In Regulatory, Spine /

WAYNE, Pa., Dec. 7, 2017 /PRNewswire/ — Camber Spine announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its SPIRA™-C Open Matrix Cervical Interbody device, an innovative interbody fusion implant, second in the SPIRA™ family to employ a novel arched design as well as Surface by Design™ technology. This clearance marks Camber’s second implant clearance in the SPIRA™ family of implant systems to be released in the U.S. market.

The SPIRA™ family of interbody implants represents the next generation of open architecture; 3-D printed, titanium implants designed to enhance fusion. The combination of smart science and smart surfaces merged with SPIRA™ Arch Technology creates an optimal environment for cell proliferation and bone growth. According to Daniel Pontecorvo, CEO at Camber Spine, “The engineers and designing surgeons leveraged the latest in 3-D printing technology to incorporate the needs at each step of the fusion process with the SPIRA™ family. To enable immediate stability, significant friction was achieved with the unique surface design. For short-term stability, other features were added to the surface design. This includes both a roughened titanium surface designed to promote bone cell proliferation, and a pore size optimized for bone ingrowth. In a way, robust ingrowth achieves a “mechanical fusion”, where we expect patients to feel better quicker. Lastly, long-term stability is achieved with the ultimate endplate-to-endplate fusion. The newly forming bone follows the multiple arches incorporated with the Surface By Design™ to encourage ongrowth and ingrowth throughout the cage. Also, using a key bone-growth principal called “Wolff’s Law”, the arched design structure enables the distribution of load and strain, helping to enhance the fusion. We are very excited about this great implant design.”

The SPIRA™ Open Matrix ALIF implant, the first product released in the SPIRA™ family, also with an open architecture and arched design, was launched only three months ago, and has already been received with great surgeon enthusiasm for the treatment of their patients. Together, with the ENZA™ ALIF implant providing simple and stable, zero-profile integrated fixation, Camber Spine is poised to be a leader in the interbody implant arena.

The Camber Spine SPIRA™-C Open Matrix Cervical Interbody device is indicated for use at one or two contiguous levels in the cervical spine, from C3-C7, in skeletally mature patients who have had six weeks of non-operative treatment for the degenerative disk disease (DDD) with up to Grade 1 spondylolisthesis. DDD is defined as neck pain of discogenic origin with the degeneration of the disc confirmed by history and radiographic studies. The Camber Spine Technologies SPIRA-C™ Open Matrix Cervical Interbody is intended to be used with additional FDA-cleared supplemental fixation systems.

About Camber Spine

Camber Spine Technologies, LLP, is a fast-growing musculoskeletal implant company founded in 2010 bringing innovative, best-in-class products to the market, providing surgeons and their patients with better treatment options. The company is committed to delivering surgeon inspired new technologies to the spine market. Camber is an ISO 13485 certified medical device company. Camber Spine Technologies, located in Wayne, Pennsylvania, markets a line of proprietary musculoskeletal products nationwide through its exclusive distributor, S1 Spine. For further information please visit www.cambermedtech.com . For inquiries about SPIRA™-C or distribution opportunities please call 484.427.7060.

All of Camber Spine Technologies’ products are proudly MADE IN THE USA.

SOURCE Camber Spine Technologies

Smith & Nephew Announce European Launch of Handheld Imaging Technology a New Era of Evidence-Based Decision Making in Wound Care

Posted On December 11, 2017 By OrthoSpineNews In Extremities /

December 11, 2017

LONDON–(BUSINESS WIRE)–Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X^TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.^2,3

Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.⁴ Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria^1,2,3in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient^1,2and can help to guide wound sampling and debridement,^1,5,6 monitor wound progression,^2,3 improve patient engagement^4,5and simplify wound documentation.¹

Clinical data from wound assessments demonstrates that incorporating the MolecuLight i:X into standard care facilitated more objective medical decision making and led to up to 9 times faster wound healing¹ and 54% more accurate swabbing.⁷

“The MolecuLight i:X enables healthcare professionals to see what they have never been able to see before“ said Paolo Di Vincenzo, Smith & Nephew’s Senior Vice President Global Marketing, Wound. “We are proud to partner with MolecuLight Inc. and bring this innovative technology to our customers. It strongly complements our range of advanced wound care products and we believe is set to start a revolution in wound care clinical practice.”

“For the first time clinicians can accurately sample a wound in situ to determine if bacteria are present as well as more effectively debride a wound under fluorescence visualisation. These are fundamental areas of everyday wound care that have remained suboptimal for too long, until now,” says Dr. Ralph DaCosta, Founder, Chief Scientific Officer and Director, MolecuLight Inc.

An estimated 2 million people are living with a chronic wound across Europe and an estimated 16% of all chronic wounds remain unresolved after a year or longer.^9,10,11 Ensuring wounds are appropriately diagnosed and treated is a priority for healthcare providers across Europe, reducing cost and improving outcomes for patients.

“Not only has the MolecuLight i:X transformed my department’s clinical decision making in terms of targeting sampling and debridement and improving antimicrobial stewardship, but the benefit to patients has also been exciting to see,” says Rosemary Hill*, Canadian Wound Ostomy Continence Nurse Clinician, Lions Gate Hospital, Vancouver. “By being able to engage patients in their wound healing progress, and by showing them the real-time images, we can reduce anxiety, and provide reassurance regarding the diminishing burden of bacteria.”

The MolecuLight i:X Imaging Device is approved by Health Canada (Medical License #95784) and has CE Marking (Certificate # G1160292355002) for sale in the European Union. The MolecuLight i:X Imaging Device is not available in the US.

Full press pack is available at: http://www.smith-nephew.com/news-and-media/media-releases/news/european-launch-of-handheld-imaging-technology-heralds-new-era-of-evidence-based-decision-making

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

To learn more about what we do to help reduce wound infection, please visit www.closertozero.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

^◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

About MolecuLight Inc.
MolecuLight Inc. is a privately owned, Canadian medical imaging company delivering real-time fluorescence image-guidance solutions that provide clinicians with new information about wound bacterial burden and wound surface area to assist clinicians in making improved diagnostic and treatment decisions.

The MolecuLight i:X is manufactured by MolecuLight® Inc.
MaRS Centre, South Tower 101 College St., Suite 200 Toronto, ON M5G 1L7 Canada
T +1 647.362.4684 F +1 647.362.4730
www.moleculight.com

® Registered trademark acknowledged

[tm] All trademarks acknowledged
MolecuLight i:X and Look to Heal are registered trademarks of MolecuLight Inc in Canada, the US and the UK. MolecuLight DarkDrape is a registered trademark of MolecuLight® Inc in Canada. Other jurisdictions pending

The MolecuLight i:X is distributed by Smith & Nephew
Wound Management
Smith & Nephew Medical Ltd, 101 Hessle Road, Hull HU3 2BN, UK
T +44 (0) 1482 225181 F +44 (0) 1482 328326
www.smith-nephew.com
All Trademarks acknowledged
©October 2017 Smith & Nephew
AWM-AWD-11878

References:

1. DaCosta RS et al. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3).

2. MolecuLight Inc. PN 1189 MolecuLight i:X User Manual. 2016.

3. MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial Presence with the MolecuLight i:X. 2016.

4. Hoeflok J et al. Pilot clinical evaluation of surgical site infections with a novel handheld fluorescence imaging device. Proceedings of the Annual Military Health System Research Symposium (MHSRS); 2014 Aug 18- 21; Fort Lauderdale, FL.

5. Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at: CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference (CAWC); 2016 Nov 3-6, Niagara Falls, ON.

6. Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.

7. Ottolino-Perry K et al. Improved detection of wound bacteria using fluorescence image guided wound sampling in diabetic foot ulcers. Int Wound J. 2017 Feb 28. doi: 10.1111/iwj.12717.

8. Posnett J et al. J. Wound Care (April 2009), The Resource Impact of Wounds on Health-care Providers in Europe, vol.18 (4).

9. Lindholm C and Searle R. Wound management for the 21st century: combining effectiveness and efficiency. Int Wound J. 2016 Jul;13 Suppl 2:5-15.

10. Siddiqui AR and Bernstein JM. Chronic wound infection: facts and controversies. Clin Dermatol. 2010;28:519–26.

11. Vowden P. Hard-to-heal wounds made easy. Wounds International, Schofield Healthcare Media Ltd: Norwich, UK, 2011;2. URL: http:// www.woundsinternational.com.

* Rosemary Hill is a paid consultant of Smith & Nephew or MolecuLight Inc.

Contacts

Media Enquiries
Rachel Cunningham
Rachel@roadcommunications.co.uk
+4420 8995 5832
or
Fabienne Merlet
Fabienne@roadcommunications.co.uk
+4420 8995 5832
or
Dave Snyder
Smith & Nephew
+1 (978) 749-1440

Sports Medicine Market by Product, Application & Region – Global Forecast to 2022

Posted On December 11, 2017 By OrthoSpineNews In Sports Medicine /

DUBLIN, Dec. 11, 2017 /PRNewswire/ —

The “Sports Medicine Market – Global Forecast to 2022” report has been added to Research and Markets’ offering.

The global sports medicine market is projected to reach USD 8.24 Billion by 2022 from USD 5.78 Billion in 2017, at a CAGR of 7.4% during the forecast period. The increasing incidence of sports injuries, continuous influx of new products and treatment modalities, and developments in the field of regenerative medicine are some of the major factors driving the growth of the global sports medicine market.

The sports medicine market is segmented on the basis of product, application, and region. On the basis of product, the global market is segmented into body reconstruction products, body support & recovery products, and accessories. The body reconstruction products segment is further categorized into implants, fracture & ligament repair devices, arthroscopy devices, prosthetics, and orthobiologics. The orthobiologics segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the recent developments in regenerative medicine, allografts, and stem cell therapy.

The body support & recovery products segment is further divided into braces and supports, compression clothing, and physiotherapy equipment. The physiotherapy equipment segment is further categorized into thermal therapy, electrostimulation, and other therapies.

Based on application, the market is segmented into shoulder, foot and ankle, elbow & wrist, back & spine, hip & groin, knee, and other injuries (head, face, and finger injuries). In 2017, the knee injuries segment is estimated to command the largest share of the sports medicine market. Growth in the knee injuries segment can be attributed to the increasing participation in sports like football and basketball at a younger age, resulting in high prevalence of knee injuries.

The elbow and wrist injuries segment is estimated to register the highest CAGR during to forecast period. This can be attributed to the increasing number of injuries in sports, like rowing, racquet sports, and golf, where there is a repetitive overuse of elbow and wrists.

Companies Mentioned

Arthrex
Breg
Conmed
Depuy Synthes Companies
Djo Global
Medtronic
Mueller Sports Medicine
Performance Health International Limited
Rti Surgical
Smith & Nephew
Stryker
Wright Medical Group
Zimmer Biomet

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Sports Medicine Market, By Product

7 Sports Medicine Market, By Application

8 Sports Medicine Market, By Region

9 Competitive Landscape

10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/4f5vzv/sports_medicine

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

EIT Emerging Implant Technologies Announces Agreement with HCA

Posted On December 11, 2017 By OrthoSpineNews In Spine, Top Stories /

ROSWELL, GA (PRWEB) DECEMBER 11, 2017

Emerging Implant Technologies GmbH (EIT), a German medical device manufacturer exclusively focused on creating innovative technologies for spinal application by utilizing additive manufacturing, announces that it has now successfully completed the contracting process with HealthTrust related to an HCA contract and is now able to offer all interbody products for Cervical, ALIF, TLIF and PLIF procedures in the 177 hospitals and 119 freestanding surgery centers located throughout the United States.

EIT Cellular Titanium® is a 3D printed porous titanium structure that has been designed according to scientific insights on ideal pore shape and size to optimize cell proliferation and bone ingrowth.

With the addition of this contract, EIT is poised to continue its aggressive growth pattern in the United States. EIT believes that this will create more unique opportunities to work with HCA surgeons to evaluate and take advantage of the validated structure and many other unique features that differentiate EIT from other 3D printed products.

The contract approval was pursued and successfully completed by Ortho Sales Partners. Josh Sandberg, President of OSP said, “This is a huge milestone that we have been able to help achieve at an unusually early stage in EIT’s development. That is a credit to the strength of this product offering and we are excited about the opportunity to work with HCA facilities in helping them lower the overall cost of these spine procedures.”

“EIT´s goal is to improve spine care using the advantages of 3D printing technology and cope with given pricing and reimbursement structures. We are delighted that HCA/HealthTrust is interested in working with EIT. This will help us to get quicker market access in the United States” said Guntmar Eisen, cofounder and CEO of EIT.

In addition to the contract, EIT is currently finalizing an action plan with HCA leadership to understand the economic impact this novel technology will have on fusion rates, implant costs and the need for high cost osteobiologics. Further details of this proposal will be announced at a later time.
________

About EIT

EIT is the first medical device manufacturer to exclusively focus on implants for spinal alignment, that are designed according to latest published science on optimal bone ingrowth in porous titanium scaffolds and produced with additive manufacturing methods. EIT was founded in 2014 by Hans Eekhof and Guntmar Eisen.

The EIT implants are made of EIT Cellular Titanium®, that addresses the clinical shortcomings of the current cage designs and materials (non-fusion, biocompatibility, subsidence, migration and imaging distortion), thereby obtaining very promising fusion results and improved clinical outcome due to the qualities of the porous 3-D printing of titanium. The highly porous titanium scaffold ensures extensive bone ingrowth as a result of its specific design and elasticity close to the cancellous bone. Due to its unique design with a porosity of 80% the EIT implants ensure uncompromised imaging on X-ray and MRI and enabling excellent follow up on defining bone ingrowth and fusion with CT.

A complete portfolio of Smart Spinal Implants™ based on EIT Cellular Titanium® is available for the cervical and lumbar spine, with an extensive choice in footprint sizes, heights and lordosis angles to support the recreation of sagittal balance and alignment. Since 2014 over 12.000 EIT cases have been performed in over 15 markets globally.

Omnia Medical: First PEEK-OPTIMA™ HA Enhanced Vertebral Body Replacement System to Enter US Market

Posted On December 11, 2017 By OrthoSpineNews In Regulatory, Spine /

THORNTON CLEVELEYS, UK (PRWEB) DECEMBER 07, 2017

‘Omnia Medical VBR’ has been granted the first US FDA 510(k) clearance for a vertebral body replacement (VBR) system manufactured from PEEK-OPTIMA™ HA Enhanced polymer, from Invibio Biomaterial Solutions, for use in the thoracolumbar spine to replace a collapsed, damaged, or unstable vertebral body. This advancement was the result of a three-way collaboration: orthopaedic implant company Omnia Medical partnered with JALEX Medical on product development and regulatory activities and with Invibio Biomaterial Solutions, who pioneered medical PEEK.

Robert Gewirtz, MD – Neurosurgeon, Columbus, Ohio, comments on the innovative orthopaedic product: “Omnia Medical VBR is an intuitive device that is easy for the surgeon to use, and the benefits of hydroxyapatite incorporated into the structure of the implant is a real advance for our patients as it potentially offers improved outcomes.I am happy that I was able to partner in this collaboration to help bring the product to market.”

The novel single-use device is available in two footprints and allows fine adjustments of height and lordosis using spacers and endplates. It features a hollow center and holes to accommodate autograft or allograft while encouraging formation of new bone and includes anti-migration features.

In PEEK-OPTIMA HA Enhanced, Hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, is fully integrated into the polymer matrix, and not simply coated. Invibio´s enhanced biomaterial offers all the clinical advantages of PEEK OPTIMA Natural including a modulus similar to cortical bone, reduced stress shielding and artifact-free imaging that allows for clear fusion assessment. It has been shown to improve bone apposition compared to unfilled PEEK-OPTIMA Natural in a pre-clinical ovine model at 4 weeks and 12 weeks,(1) and also demonstrated performance advantages in a pre-clinical cervical spine fusion model in sheep at 6 and 12 weeks.(2) In addition, as observed by surgeons, early clinical results have shown solid fusions with dense bone apposition at 6 months and beneficial clinical outcomes for patients, revealing specific improvements in overall pain and neurological function,(3) when a PEEK-OPTIMA HA Enhanced interbody fusion device was used.

Steve Anderson, Vice President of Marketing at Omnia Medical concludes: “We are happy to be the first to be granted FDA 510(k) clearance for a vertebral body replacement (VBR) system manufactured from PEEK-OPTIMA HA Enhanced biomaterial. This unique material combination is a great option for the VBR application due to the large amount of natural anatomy removed during the procedure. Working with JALEX Medical and Invibio Biomaterial Solutions was an excellent experience – and will hopefully enable surgeons and patients to benefit from the new solutions.”

For more information please visit http://www.omniamedical.com, http://www.jalexmedical.com and https://invibio.com.

REFERENCES
1.    Study evaluated the in vivo response to PEEK-OPTIMA Natural and PEEK-OPTIMA HA Enhanced in a large animal model. Data on file at Invibio. This has not been correlated with human clinical experience.
2.    Study evaluated the in vivo response to PEEK-OPTIMA Natural, PEEK-OPTIMA HA Enhanced and allograft in a cervical spine fusion model in sheep. Data on file at Invibio. This has not been correlated with human clinical experience.
3.    Testimonials presented have been provided by participating orthopaedic surgeons. Their view and experience are their own and do not necessarily reflect those of others. “Invibio” disclaims any liabilities or loss in connection with the information herein

Next-Generation High-Definition Visualization System for Minimally Invasive Surgery Introduced by DePuy Synthes

Posted On December 6, 2017 By OrthoSpineNews In Recon, Spine, Top Stories /

LAS VEGAS, Dec. 6, 2017 /PRNewswire/ — Today, the PUREVUE™ Visualization System was unveiled at the Orthopaedic Summit 2017: Evolving Techniques. This new offering from DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, is a state-of-the-art imaging platform for minimally invasive endoscopic surgery.

Approximately 18.6 million endoscopic procedures are performed each year in the United States.¹ In these procedures, case efficiency and patient outcomes are often linked to how well the surgeon can see the targeted anatomy.

The PUREVUE Visualization System combines a light source, image processer and local image management for a reduced operating room (OR) footprint, and includes intuitive touch-screen navigation and customizable settings for many minimally invasive surgery (MIS) applications. The autoclavable camera head features a proprietary sensor designed for endoscopy, that delivers native HD image acquisition for a clear view throughout the procedure that is further enhanced by multiple monitor options, including ultra-high-definition 4K. The forward-compatible system is also augmented by a wide range of visualization accessories.

“With Americans living longer and seeking shorter recovery times, the call for minimally invasive procedures is accelerating,” said Stephanie Chamberlain, Vice President and Global Platform Leader, DePuy Synthes Mitek Sports Medicine. “We are committed to bringing forward innovation that responds to evolving patient needs and the PUREVUE Visualization System is an example of how our advanced technologies enable high quality patient care.”

The PUREVUE Visualization System also completes the company’s capital equipment offering in arthroscopy, a type of endoscopic surgery focused on joint anatomy, which includes the VAPR VUE™ Radiofrequency System and the FMS VUE™ Fluid Management and Tissue Debridement System. Together, these solutions bolster Mitek Sport Medicine’s portfolio of implants and instrumentation used for a wide spectrum of arthroscopic soft tissue procedures.

About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

¹ Perry, Anne F., et al. “Burden of Gastrointestinal Disease in the United States: 2012 Update” Gastroenterology. 2012 November; 143(5): 1179–1187.e3. doi:10.1053/j.gastro.2012.08.002 Update.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.

DSUS/MTK/1117/1100(1)
December 2017

SOURCE DePuy Synthes

Month: December 2017

Related Links

Contacts

Related Stories

Related Links

Contacts

Related Links

Related Links